| Literature DB >> 24740226 |
Pierre Foskett1, Gareth Gerrard, Letizia Foroni.
Abstract
The BCR-ABL1 fusion gene, the causative lesion of chronic myeloid leukemia (CML) in >95 % of newly presenting patients, offers both a therapeutic and diagnostic target. Reverse-transcription quantitative polymerase chain reaction technology (RT-qPCR), utilizing primer-probe combinations directed to exons flanking the breakpoint junctional region, offers very high levels of both specificity and sensitivity, in a scalable, robust, and cost-effective assay.Entities:
Mesh：
Substances：
Year: 2014 PMID： 24740226 DOI： 10.1007/978-1-4939-0733-5_11
Source DB: PubMed Journal: Methods Mol Biol ISSN： 1064-3745